Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $31.93, for a total value of $159,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, September 12th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $31.86, for a total value of $159,300.00.
  • On Tuesday, August 8th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $30.57, for a total value of $152,850.00.

Shares of Genomic Health, Inc. (GHDX) traded up 1.85% on Wednesday, hitting $32.54. The company had a trading volume of 113,171 shares. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $33.97. The firm has a 50-day moving average price of $31.42 and a 200 day moving average price of $31.64. The company’s market capitalization is $1.13 billion.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. During the same quarter in the prior year, the firm posted ($0.18) earnings per share. The business’s revenue was up 4.3% compared to the same quarter last year. Equities analysts expect that Genomic Health, Inc. will post ($0.02) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) COO Sells $159,650.00 in Stock” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/11/genomic-health-inc-ghdx-coo-sells-159650-00-in-stock.html.

GHDX has been the subject of several research reports. Zacks Investment Research cut Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reissued a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. BidaskClub cut Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Canaccord Genuity reduced their price objective on Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, August 15th. Finally, Cowen and Company reissued a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $31.83.

Several hedge funds and other institutional investors have recently modified their holdings of GHDX. Dubuque Bank & Trust Co. boosted its stake in Genomic Health by 8.4% in the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 379 shares during the period. SG Americas Securities LLC boosted its stake in Genomic Health by 37.8% in the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 1,679 shares during the period. Legal & General Group Plc boosted its stake in Genomic Health by 48.7% in the 1st quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 2,038 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Genomic Health in the 1st quarter valued at $218,000. Finally, Parametric Portfolio Associates LLC boosted its stake in Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after purchasing an additional 441 shares during the period. Institutional investors own 88.90% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.